Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4492505 | 1.00 | KMT2A (0.57) | KMT2AMEN1MAPK1POLBCYP1A2 | |
| SCHEMBL21949121 | 1.00 | KMT2A (0.57) | KMT2AMEN1MAPK1POLBCYP1A2 | |
| SCHEMBL29700089 | 0.85 | KMT2A (0.61) | KMT2AMEN1MAPK1POLBCYP1A2 | |
| SCHEMBL14584633 | 0.85 | MEN1 (0.53) | KMT2AMEN1MAPK1POLBCYP1A2 | |
| SCHEMBL29642620 | 0.85 | KMT2A (0.61) | KMT2AMEN1MAPK1POLBCYP1A2 | |
| SCHEMBL24576668 | 0.85 | KMT2A (0.61) | KMT2AMEN1MAPK1POLBCYP1A2 | |
| SCHEMBL7826640 | 0.85 | MEN1 (0.53) | KMT2AMEN1MAPK1POLBCYP1A2 | |
| SCHEMBL15352488 | 0.85 | KMT2A (0.61) | KMT2AMEN1MAPK1POLBCYP1A2 | |
| SCHEMBL3531035 | 0.85 | KMT2A (0.61) | KMT2AMEN1MAPK1POLBCYP1A2 | |
| SCHEMBL3531037 | 0.85 | KMT2A (0.61) | KMT2AMEN1MAPK1POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524841-B2 | 4,4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-15 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1505067-A1 | 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-09 | — | — | EP | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
| EP-0155828-B1 | PROCESS FOR MAKING 2-OXINDOLE-1-CARBOXAMIDES AND INTERMEDIATES THEREFOR | PFIZER INC. (US) | 1990-09-19 | — | — | EP | disclosed |
| EP-0156603-B1 | 3-SUBSTITUTED 2-OXINDOLE-1-CARBOXAMIDES AS ANALGESIC AND ANTI-INFLAMMATORY AGENTS | PFIZER INC. (US) | 1989-08-23 | — | — | EP | disclosed |
| EP-0164860-B1 | N,3-DISUBSTITUTED 2-OXINDOLE-1-CARBOXAMIDES AS ANALGESIC AND ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1989-07-05 | — | — | EP | disclosed |
| EP-0175551-B1 | ANALGESIC AND ANTIINFLAMMATORY 1,3-DIACYL-2-OXINDOLE COMPOUNDS | PFIZER INC. (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4665194-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | PFIZER INC. (US) | 1987-05-12 | — | — | US | disclosed |
| US-4658037-A | RHEUMATIC DISEASES | PFIZER INC. (US) | 1987-04-14 | — | — | US | disclosed |
| US-4652658-A | Process for making 2-oxindole-1-carboxamides and intermediates therefor | PFIZER INC. (US) | 1987-03-24 | — | — | US | disclosed |
| EP-0175551-A1 | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds | PFIZER INC. (US) | 1986-03-26 | — | — | EP | disclosed |
| US-4569942-A | N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents | PFIZER INC. (US) | 1986-02-11 | — | — | US | disclosed |
| EP-0164860-A1 | N,3-disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents | PFIZER INC. (US) | 1985-12-18 | — | — | EP | disclosed |
| US-4556672-A | 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0156603-A2 | 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0155828-A2 | Process for making 2-oxindole-1-carboxamides and intermediates therefor | PFIZER INC. (US) | 1985-09-25 | — | — | EP | disclosed |
| EP-0153818-A2 | 1,3-Disubstituted 2-oxindoles as analgesic and anti-inflammatory agents | PFIZER INC. (US) | 1985-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | KMT2A 3261/4885MEN1 3556/4885MAPK1 1077/4885 |
| US-20070037851-A1 | Inhibits binding of CCR3 ligands such as eotaxins to their target cells; inhibits physiological effects of binding; therapeutic and prophylactic agents for asthma, rhinitis, dermatitis, urticaria, conjunctivitis, inflammatory bowel; tissue infiltration of eosinophils, basophils, activated T cells | CCR3, CCR1, CCR4 | KMT2A 4002/4885MEN1 4549/4885MAPK1 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.